Qsymia

Qsymia is a new drug representing a combination of phentermine and topiramat. In clinical trials showed small, but statistically significant effect of weight reduction in comparison with group of placebo. Loss of weight was also bound to improvement of indicators of level of a glucose of a blood, arterial pressure, cholesterin level.

Qsymia was developed by the pharmaceutical company Vivus. Phentermine represents sympathetic amine, a stimulator which has anorexigenic effect, topiramat is anticonvulsant drug as often cramps are side effect at weight loss. Nevertheless the exact mechanism of effect of drugs remains obscure.

In 2012 drug FDA for treatment of obesity at people with a body weight index from 27 kg/m ² - 30 kg/m ² above, and also at least with one of associated diseases - a diabetes mellitus 2 types, hypertonia, a dislipidemiya was approved. Do not forget take Bronhalamin for better results.

Drug is available in any certified retail drugstore of the USA, and also the registered mail in network of drugstores.

On October 18, 2012 the Committee on medicinal preparations for the person (CHMP) refused carrying out the marketing company of drug against an obesity as considers that Qsymia represents potential threat for cardiovascular system (it is known that phentermine enlarges heart rate, but its effects in long-term researches are unknown), a nervous system (negative cognitive and psychological effects were taped), presumably has teratogen effect.